These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 37921427)
21. The current status and future of targeted-immune combination for hepatocellular carcinoma. Hao L; Li S; Ye F; Wang H; Zhong Y; Zhang X; Hu X; Huang X Front Immunol; 2024; 15():1418965. PubMed ID: 39161764 [TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes. Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813 [TBL] [Abstract][Full Text] [Related]
23. Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy. Hage C; Hoves S; Ashoff M; Schandl V; Hört S; Rieder N; Heichinger C; Berrera M; Ries CH; Kiessling F; Pöschinger T PLoS One; 2019; 14(7):e0219517. PubMed ID: 31291357 [TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint therapy in liver cancer. Xu F; Jin T; Zhu Y; Dai C J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754 [TBL] [Abstract][Full Text] [Related]
25. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720 [TBL] [Abstract][Full Text] [Related]
26. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Bai J; Liang P; Li Q; Feng R; Liu J Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384 [TBL] [Abstract][Full Text] [Related]
29. Recent developments with immunotherapy for hepatocellular carcinoma. Waidmann O Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439 [TBL] [Abstract][Full Text] [Related]
30. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials. Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1. Chui NN; Cheu JW; Yuen VW; Chiu DK; Goh CC; Lee D; Zhang MS; Ng IO; Wong CC Hepatol Commun; 2022 Jan; 6(1):178-193. PubMed ID: 34558800 [TBL] [Abstract][Full Text] [Related]
32. Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma. Pourhamzeh M; Asadian S; Mirzaei H; Minaei A; Shahriari E; Shpichka A; Es HA; Timashev P; Hassan M; Vosough M Mol Cell Biochem; 2023 Jan; 478(1):23-37. PubMed ID: 35708866 [TBL] [Abstract][Full Text] [Related]
33. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917 [TBL] [Abstract][Full Text] [Related]
34. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma. Huang X; Qiu Z; Li L; Chen B; Huang P Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M Front Immunol; 2021; 12():799455. PubMed ID: 35069581 [TBL] [Abstract][Full Text] [Related]
36. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345 [TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Hargadon KM; Johnson CE; Williams CJ Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692 [TBL] [Abstract][Full Text] [Related]
38. Recent advances in the clinical development of immune checkpoint blockade therapy. Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647 [TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Atkins MB; Clark JI; Quinn DI Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639 [TBL] [Abstract][Full Text] [Related]
40. A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer. Kim E; Ahn H; Park H Mamm Genome; 2021 Aug; 32(4):223-231. PubMed ID: 33783613 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]